Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Napster Co-Founder Funds Immunotherapy Research Project

By Drug Discovery Trends Editor | April 14, 2016

Parker (left) made a generous donation to cancer research. (Credit: The Parker Institute)Sean Parker, the entrepreneur behind music-sharing service Napster, is providing a $250 million grant to support a consortium aimed at supporting immunotherapy research.

This venture, a non-profit named the Parker Institute for Cancer Immunotherapy, will bring together more than 300 scientists from six major academic cancer research centers, according to The Washington Post. Stanford, Memorial Sloan Kettering Cancer Center, and the University of Pennsylvania are some of the members taking part in this endeavor.

One member from each of the participating institutions will constitute a steering committee, which will establish the group’s research agenda as well as enable better collection of data and clinical trials across all of the involved labs.

It’s a similar strategy being implemented in Vice President Joe Biden’s Cancer Moonshot. A key tenet of this initiative is to “break down silos” regarding communication between the public and private sectors as a way to find a cure for these diseases.

Plus, The Washington Post noted another unique innovation of Parker’s project is that the team will retain ownership of the intellectual property while taking charge on licensing and negotiating potential market opportunities with drugmakers.

Parker provided this money because he felt immunotherapy research “is at a turning point and would benefit from research that is done without regard for its costs,” reported USA Today.

This class of drugs essentially activates the body’s immune system in order to combat foreign pathogens. Early studies have shown these treatments have promise, but more research needs to be done to ensure these drugs can work on a large group of patients and are cost-effective.

R&D 100 AWARD ENTRIES NOW OPEN:

Establish your company as a technology leader! For more than 50 years, the R&D 100 Awards have showcased new products of technological significance. You can join this exclusive community!  Learn more.


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE